

**Edward Garmey, M.D.** Chief Medical Officer and Senior Vice President at Cerulean Pharma, Inc., a publicly-traded clinical-stage oncology company located in Cambridge, MA. (USA) which focuses on the design and development of nanopharmaceuticals differentially directed to cancer cells. Prior to being appointed to this role in May of 2011, Dr. Garmey served between 2008 and 2011 as Vice President for Clinical Development at ArQule, Inc., a cancer-focused biotechnology company located in Woburn, Ma., where he developed and oversaw multiple international clinical trials of its lead product, ARQ 197 (tivantinib). Dr. Garmey additionally served there as a clinical development liaison with external development partners and assisted in the planning and execution of a license, co-development and co-commercialization agreement for the development of ARQ 197 in the United States and Europe. Prior to arriving at ArQule, Dr. Garmey was Medical Director at GPC Biotech in Princeton, New Jersey, where he helped oversee global clinical development studies. A pediatric hematologist-oncologist by training, Dr. Garmey is a graduate of Harvard and New York Universities and completed his medical training at institutions including the Mount Sinai Medical Center (N.Y.); the Children's Hospital of Los Angeles; and the Memorial Sloan-Kettering Cancer Center (N.Y.). Dr. Garmey completed additional research fellowships at the National Institutes of Health (1998-99) and Botswana-Harvard Partnership for H.I.V. Research in Gaborone, Botswana (1999-2000) and he is a recipient of young investigators awards from the American Society of Hematology and the American Heart Association. Dr. Garmey has presented at numerous international conferences and is an author on over 30 peer-reviewed abstracts and manuscripts. In 2009, he was appointed as a medical consultant to the New York City Investment Fund and serves there as an advisor to the fund's \$1.25 Million "BioAccelerate NYC Prize" for biomedical research. Dr. Garmey lives in Boston, Massachusetts, where he serves on the scientific advisory board of the Harvard-MIT Broad Institute's Cancer Vaccine Initiative, as well as the board of visitors of Hearth, a non-profit organization dedicated to the elimination of homelessness among the elderly.